Publications

Preclinical

Categories
Preclinical
April 17, 2023
AACR
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
Poffenberger et al.
Preclinical
April 17, 2023
AACR
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Madera et al.
Preclinical
April 17, 2023
AACR
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
Von Rossum et al.
Preclinical
April 17, 2023
AACR
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Barnscher et al.
Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.
Preclinical
April 17, 2023
AACR
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Colombo et al.
Preclinical
February 22, 2023 - February 23, 2023
European Bispecific & Multispecific Antibody Congress
Design and Functional Characterization of Zanidatamab Zovodotin (ZW49), a HER2-targeting Biparatopic Antibody Drug Conjugate in Clinical Development​
Stuart Barnscher
Preclinical
December 5, 2022
Antibody Engineering & Therapeutics Conference
Novel IgG1 Cysteine Insertion Sites Enable Site-Specific Conjugation and Precise Control of Drug to Antibody Ratio
Das et al.
Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Preclinical
September 9, 2022
World ADC San Diego
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Barnscher et al.
Preclinical
May 2, 2022 - May 6, 2022
PEGS
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Petersen et al.